EU CHMP Proposes Approval for AstraZeneca’s Soliris

gMC is an uncommon, inflammatory neuromuscular disease that causes significant muscle atrophy throughout the body. Refractory gMG rapidly stimulates the terminal complement pathway and begins targeting cells within the body.

AstraZeneca’s study of Soliris therapy in children generated promising results, which served as the foundation for CHMP’S approval.
According to the Quantitive Myasthenia Gravis, a system for assessing the degree of disease based on alterations in bodily structures and capabilities, there were fewer signs of muscle weakness in subjects over 6 years old who had undergone prior inefficient immunosuppressive therapy.

Marc Dunoyer, Chief Executive Officer of Alexion stated that “if approved, Soliris would be the first targeted treatment for paediatric patients living with refractory gMG in Europe, offering the possibility of improved outcomes and quality of life”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.